Close mobile menu×
Close mobile menu

James M. McKiernan, MD

Board Certifications: 
Urology
Expertise in: 
Bladder Cancer, Cancer Care, Kidney & Adrenal Cancer, Prostate Cancer, Testicular Cancer, Urologic Oncology
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor
NY Top Doctor

Board Certifications

  • Urology

Clinical Expertise

  • Bladder Tumor
  • Genitourinary Surgery
  • Kidney Cancer
  • Major Bladder Reconstruction
  • Urologic Cancer

Education & Training

  • Columbia University College of Physicians and Surgeons
  • MD, 1993 Columbia University College of Physicians and Surgeons
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: Memorial Sloan-Kettering Cancer Center, NY

About James McKiernan

james_m._mckiernan_md_-_chair_columbia_department_of_urology

James McKiernan, MD, the John K. Lattimer Professor of Urology, is the chair of the Department of Urology of the College of Physicians and Surgeons and urologist-in-chief at NewYork-Presbyterian/Columbia. Dr. McKiernan is only the sixth physician to hold this title since the founding of the department in 1917. The Department of Urology, one of the oldest and most distinguished in the nation, consistently ranks among the top in New York and throughout the United States. NewYork-Presbyterian's urology program ranked No. 5 in the latest U.S. News & World Report ranking of America's best hospitals. In 2015, the department ranked No. 7 in NIH grant funding among academic Urology departments in America.

Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused in urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness reseach in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.

For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer.

Academic Titles

  • John K. Lattimer Professor of Urology

Administrative Positions

  • Director, Urologic Oncology
  • Chair, Department of Urology

Committee/Societies/Council Memberships

  • American Urology Association
  • Alpha Omega Alpha Medical Honor Society
  • American Urologic Association
  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • Society or Urologic Oncology
  • New York Clinical Society
  • New York Medical Surgical Society
  • Fellow New York Academy of Medicine Section of Urology

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center
  • NewYork-Presbyterian Lawrence Hospital

Languages

  • Spanish

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

MagnaCare

  • MagnaCare

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Primary

Research

Grants

A PHASE I TRIAL FOR THE USE OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLATIN (CGC) IN THE TREATMENT OF BCG-REFRACTORY NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER (P&S Industry Clinical Trial)

Jul 31 2014 - Jul 31 2019

AN INTEGRATED PHASE II/III, OPEN LABEL, RANDOMIZED, PARALLEL AND CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF CG0070 ONCOLYTIC VECTOR REGIMEN IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CARCINOMA IN SITU DISEASE (?NMIBCIS?, MEANING CIS AND CIS WITH (P&S Industry Clinical Trial)

Mar 31 2014 - Apr 3 2019

INVESTIGATION OF A NONPARTICLE ALBUMIN-BOUND MTOR INHIBITOR, NABRAPAMYCIN, FOR THE INTRAVESICAL TREATMENT OF BCG RECURRENT OR REFRACTORY NON-MUSCLE INVASIVE TRANSITIONAL CELL BLADDER CANCER (Federal Gov)

Apr 1 2013 - Dec 31 2016

EN3348-303 (P&S Industry Clinical Trial)

May 2 2011 - May 2 2016

COLUMBIA PCF EXOSOME GRANT APPLICATION (Private)

Mar 1 2012 - Feb 28 2014

EXOSOME (Private)

Feb 11 2011 - Jun 30 2012